Definitely not a fluff pr, revenue is always good news, and another pr will give more details and a nice bump in pps. Now if only they'd give us more about thier cancer research we'd be around .25 again imo
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.